PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • October 2016 •
  • 392 pages •
  • Report ID: 4599803 •
  • Format: PDF
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

Summary
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM.

It is estimated that pharmaceutical sales within the MDD market were approximately $3.2 Billion in 2015 across the 7MM. The US contributed 76.1% of these sales, generating an estimated $2.4 Billion. The large US share was predominantly due to sales from the atypical antipsychotics, such as Otsuka/BMS’ Abilify and AstraZeneca’s Seroquel XR, which have higher costs of therapy compared with other marketed antidepressants.

By the end of the forecast period in 2025, MDD sales in the 7MM are expected to grow to $5.8 Billion at a Compound Annual Growth Rate (CAGR) of 6.1% over the 10-year period. The majority of this growth is attributed to sales from the atypical antipsychotics, such as Otsuka/BMS’ Abilify, AstraZeneca’s Seroquel XR, and Otsuka/Lundbeck’s Rexulti, which are expected to collectively capture 38.9% of the global market in 2025, and generate $2.2 Billion in sales.

According to Christos Michaelides, Analyst: “Atypical antipsychotics such as Otsuka/Bristol-Myers Squibb’s Abilify, AstraZeneca’s Seroquel XR, and Otsuka/Lundbeck’s Rexulti are expected to collectively capture approximately 39% of the global market in 2025, and generate an impressive $2.2 Billion in sales. Although Abilify and Seroquel will experience some generic erosion over the forecast period, Rexulti will continue to drive sales upwards following its expected launches in the US and Europe in 2018.

The major drivers of growth of the MDD market during the forecast period include -
- The growth of the atypical antipsychotics throughout the 7MM, most notably from Otsuka/Lundbeck’s Rexulti.
- The increasing global diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.
- The potential introduction of six late-stage pipeline products into the MDD market, some of which have novel mechanisms of action (MOAs), such as Janssen’s esketamine, Alkermes’ ALKS-5461, and Allergan’s rapastinel.

The report “PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025” overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In particular, this report provides the following analysis -
- Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
- Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AbbVie, Abbott Laboratories, Abbott Laboratories, Alkermes, Allergan, Asahi Kasei, Astellas, AstraZeneca, Avanir Pharmaceuticals, Axsome Therapeutics, Bristol-Myers Squibb, e-Therapeutics, Eli Lilly, GlaxoSmithKline, Gedeon Richter, Janssen, Lundbeck, Meiji Seika, Merck & Co., Methylation Sciences, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Mochida, Moksha8, Neuralstem Pharmaceuticals, Novartis, Otsuka, Pfizer, Pierre Fabre, Royalty Pharma, Sandoz, Shionogi, Takeda, Teva Pharmaceutical.

Highlights
Key Questions Answered
- The MDD market is widely genericized. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
- There are five substantial unmet needs that exist in the MDD market. Will pipeline drugs fulfil any of the unmet needs for MDD? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
- Six late-stage pipeline products are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for MDD?

Key Findings
- The main drivers of growth in the MDD market will be the uptake of atypical antipsychotic products throughout the 7MM, most notably from Otsuka/Lundbeck’s Rexulti. These agents are forecast to be the highest selling MDD products by 2025, accounting for 38.9% of the MDD market in the 7MM.
- The six late-stage pipeline products are all adjunctive therapies aimed at treating treatment-resistant patients and aim to satisfy major unmet needs within the MDD market; providing therapies with better efficacy, improved safety profiles, and rapid onsets of action.
- The biggest barrier for growth in the MDD market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
- Growth in the MDD market is also expected to be driven by increasing diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.

Scope
- Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
- Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global MDD therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.